NASDAQ:RXII RXi Pharmaceuticals (RXII) Stock Price, News & Analysis → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free RXII Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.66▼$0.7050-Day Range$0.36▼$0.5052-Week Range$0.31▼$7.70Volume106,030 shsAverage Volume1.73 million shsMarket Capitalization$2.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get RXi Pharmaceuticals alerts: Email Address Ad Wall Street StarAI finds its first serious applicationAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About RXi Pharmaceuticals Stock (NASDAQ:RXII)Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.Read More Ad Wall Street StarAI finds its first serious applicationAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry RXII Stock News HeadlinesOctober 26, 2023 | finance.yahoo.comRex International Holding Ltd (RXI.SG)April 19, 2023 | thestreet.comGalena's Breast Cancer Vaccine Doomed to FailApril 29, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.March 20, 2023 | finance.yahoo.comQ4 2022 Catalyst Pharmaceuticals Inc Earnings CallSeptember 30, 2022 | finance.yahoo.comiShares Global Consumer Discretionary ETF (RXI)See More Headlines Receive RXII Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RXi Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2018Today4/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RXII CUSIPN/A CIK1533040 Webwww.rxipharma.com Phone(508) 767-3861FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,450,000.00 Net Margins-4,990.20% Pretax MarginN/A Return on Equity-412.15% Return on Assets-179.54% Debt Debt-to-Equity RatioN/A Current Ratio1.77 Quick Ratio1.77 Sales & Book Value Annual Sales$10,000.00 Price / Sales298.72 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book0.89Miscellaneous Outstanding Shares4,380,000Free FloatN/AMarket Cap$2.99 million OptionableNot Optionable Beta2.07 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesGerrit DispersynPresident, Chief Executive Officer & DirectorJames CardiaVice President-Business OperationsCaitlin KontulisSecretary, VP-Finance & AdministrationSimon FrickerVice President-ResearchKey CompetitorsAridis PharmaceuticalsNASDAQ:ARDSAtrecaNASDAQ:BCELAraviveNASDAQ:ARAVPhio PharmaceuticalsNASDAQ:PHIO60 Degrees PharmaceuticalsNASDAQ:SXTPView All Competitors RXII Stock Analysis - Frequently Asked Questions How were RXi Pharmaceuticals' earnings last quarter? RXi Pharmaceuticals Co. (NASDAQ:RXII) issued its earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.16. The biotechnology company earned $0.06 million during the quarter, compared to analyst estimates of $0.02 million. RXi Pharmaceuticals had a negative trailing twelve-month return on equity of 412.15% and a negative net margin of 4,990.20%. When did RXi Pharmaceuticals' stock split? RXi Pharmaceuticals's stock reverse split before market open on Monday, January 8th 2018. The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of RXi Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other RXi Pharmaceuticals investors own include Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Auris Medical (EARS), Endologix (ELGX), Idera Pharmaceuticals (IDRA), Synergy Pharmaceuticals (SGYP), Anavex Life Sciences (AVXL), Micron Technology (MU) and This page (NASDAQ:RXII) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RXi Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
